AU · rank #19 · 2026-07-22
AVR
NASDAQ · $823M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.612 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.00 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.197 |
| Analyst upside Consensus target $15.33 | +80.6% |
| Momentum acceleration 3-month minus 12-month momentum. | +11.68% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.75 |
| Gross margin TTM | +74.3% |
| 52w high | $11.06 |
| Market cap (USD) | $823M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
AVR is a pre-commercial structural heart company developing the DurAVR THV system for TAVR, with PARADIGM pivotal enrollment advancing across multiple geographies.
Rationale
The quant setup is supported by extreme sell-side upside (80.6%), a very bullish average rating (4.75/5), and recent operating catalysts like first U.S. patients treated, CMS reimbursement support, and continued clinical data presentation.
Material risks
- 1AVR has no meaningful commercial revenue or backlog yet, so the upside case still depends on clinical execution and eventual market access rather than proven demand.
- 2Ongoing cash burn and large cumulative losses make the name dependent on favorable capital markets while PARADIGM and commercialization remain in development.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.